April 25th 2024
Findings from the CARTITUDE-2 trial support the use of cilta-cel in patients with multiple myeloma, says Tina Glow, AAS, RN, BSN.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
HPN217 Receives FDA Fast Track Designation for Relapsed/Refractory Multiple Myeloma
March 9th 2022The FDA granted fast track designation to the BCMA-targeting Tri-specific T-cell Activating Construct, HPN217, for patients with relapsed or refractory multiple myeloma who received at least 4 lines of prior therapy.
Thomas G. Martin, MD, Discusses Approval of Cilta-Cel in R/R Multiple Myeloma
March 4th 2022In an interview with CancerNetwork®, Thomas G. Martin spoke about how the approval of ciltacabtagene autoleucel will likely dramatically impact the standard of care for patients with relapsed/refractory multiple myeloma.
Flow-MRD Sensitive and Appropriate Tool for Evaluating Responses in Newly Diagnosed Multiple Myeloma
February 11th 2022A substudy of the European‐Myeloma-Network‐02/Hovon‐95 trial suggests flow cytometry–based monitoring of minimal residual disease is effective for longitudinal evaluation of responses in patients with multiple myeloma.
Yael Cohen, MD, on MRD Negativity Following Treatment With Cilta-Cel in Refractory Myeloma
January 24th 2022In an interview with CancerNetwork®, Yael Cohen, MD, discusses how treatment with ciltacabtagene autoleucel resulted in a high rate of minimal residual disease negativity in patients diagnosed with lenalidomide-refractory multiple myeloma.
Fonseca on Findings for First- Vs Second-Line Daratumumab for Transplant-Ineligible Myeloma
January 16th 2022CancerNetwork® spoke with Rafael Fonseca, MD, about findings from a simulation using real-world data sets to compare the utility of daratumumab-containing regimens as either frontline or second-line therapy.
Jakubowiak on Responses in Subgroups of Patients With Myeloma Who Received Cilta-Cel
January 14th 2022In an interview at the 2021 ASH Annual Meeting, Andrzej Jakubowiak, MD, PhD, dives into response outcomes in different patient subsets of the phase 1/2b CARTITUDE-1 trial of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.
Belantamab Mafodotin Combination Yields Promising Safety Profile in Relapsed/Refractory Myeloma
January 10th 2022A triplet combination of belantamab mafodotin-blmf plus pomalidomide and dexamethasone yielded a manageable safety profile in a population of patients with relapsed/refractory multiple myeloma.
Jakubowiak Talks CAR T-Cell Therapy in Heavily Pretreated Myeloma at 2021 ASH
January 10th 2022In an interview at the 2021 ASH Annual Meeting, Andrzej Jakubowiak, MD, PhD, describes how CAR T-cell therapy for patients with heavily pretreated myeloma has the potential significantly impact response and survival outcomes.
Jakubowiak Talks Daratumumab Quadruplet Therapy and the GRIFFIN Study at 2021 ASH
January 7th 2022In an interview at the 2021 ASH Annual Meeting, Andrzej Jakubowiak, MD, PhD, talks about daratumumab-based quadruplet therapies being evaluated in clinical trials and the potential impact they’ll have on the multiple myeloma treatment landscape.